WO2004030634A3 - Therapeutic compositions - Google Patents

Therapeutic compositions Download PDF

Info

Publication number
WO2004030634A3
WO2004030634A3 PCT/US2003/031717 US0331717W WO2004030634A3 WO 2004030634 A3 WO2004030634 A3 WO 2004030634A3 US 0331717 W US0331717 W US 0331717W WO 2004030634 A3 WO2004030634 A3 WO 2004030634A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic compositions
therapeutic
enclosed
making
methods
Prior art date
Application number
PCT/US2003/031717
Other languages
French (fr)
Other versions
WO2004030634A2 (en
Inventor
David Bumcrot
Nagesh Mahanthappa
Original Assignee
Alnylam Pharmaceuticals Inc
David Bumcrot
Nagesh Mahanthappa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc, David Bumcrot, Nagesh Mahanthappa filed Critical Alnylam Pharmaceuticals Inc
Priority to AU2003282722A priority Critical patent/AU2003282722A1/en
Publication of WO2004030634A2 publication Critical patent/WO2004030634A2/en
Publication of WO2004030634A3 publication Critical patent/WO2004030634A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

Therapeutic siRNAs and methods of making and using are enclosed.
PCT/US2003/031717 2002-10-02 2003-10-02 Therapeutic compositions WO2004030634A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003282722A AU2003282722A1 (en) 2002-10-02 2003-10-02 Therapeutic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41569802P 2002-10-02 2002-10-02
US60/415,698 2002-10-02

Publications (2)

Publication Number Publication Date
WO2004030634A2 WO2004030634A2 (en) 2004-04-15
WO2004030634A3 true WO2004030634A3 (en) 2004-09-23

Family

ID=32069900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031717 WO2004030634A2 (en) 2002-10-02 2003-10-02 Therapeutic compositions

Country Status (2)

Country Link
AU (1) AU2003282722A1 (en)
WO (1) WO2004030634A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005003788A1 (en) * 2005-01-19 2006-07-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum siRNA molecules for the treatment of blood vessels
KR101141544B1 (en) 2009-03-13 2012-05-03 한국과학기술원 Multi-conjugate of siRNA and preparing method thereof
ES2804764T3 (en) 2009-06-01 2021-02-09 Halo Bio Rnai Therapeutics Inc Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
CA2988603A1 (en) 2015-06-15 2016-12-22 Mpeg La, Llc Defined multi-conjugate oligonucleotides
AU2016312530A1 (en) 2015-08-24 2018-03-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
MX2019009347A (en) 2017-02-06 2019-10-07 Mpeg La Llc Multimeric oligonucleotides having decreased kidney clearance.
WO2024059618A2 (en) 2022-09-13 2024-03-21 Arsenal Biosciences, Inc. Immune cells having co-expressed tgfbr shrnas
WO2024059824A2 (en) 2022-09-16 2024-03-21 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELBASHIR ET AL: "RNA interference is mediated by 21- and 22-nucleotide RNAs", GENES AND DEVELOPMENT, vol. 15, 2001, pages 188 - 200, XP002206453 *
FIRE ET AL: "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans", NATURE, vol. 391, 19 February 1998 (1998-02-19), pages 806 - 811, XP002977033 *
PAUL ET AL: "Effective expression of small interfering RNA in human cells", NATURE BIOTECHNOLOGY, vol. 29, May 2002 (2002-05-01), pages 505 - 508, XP001121066 *
SUI ET AL: "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells", PNAS, vol. 99, no. 8, 16 April 2002 (2002-04-16), pages 5515 - 5520, XP002964701 *
TUSCHL ET AL: "Targeted mRNA degradation by double-stranded RNA in vitro", GENES AND DEVELOPMENT, vol. 13, 1999, pages 3191 - 3197, XP002945265 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation

Also Published As

Publication number Publication date
AU2003282722A8 (en) 2004-04-23
WO2004030634A2 (en) 2004-04-15
AU2003282722A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
WO2004080406A3 (en) Therapeutic compositions
WO2004091515A3 (en) iRNA CONJUGATES
WO2004091572A3 (en) Cochleate compositions directed against expression of proteins
WO2005110396A3 (en) Nitrated lipids and methods of making and using thereof
AU2003299509A1 (en) Crosslinked compounds and methods of making and using thereof
PL375691A1 (en) Imidazolopyridines and methods of making and using the same
AU2003280116A1 (en) Methods of making endoprostheses
AU2002950862A0 (en) Furanone derivatives and methods of making same
AU2003285012A1 (en) Compositions comprising zopiclone derivatives and methods of making and using the same
EP1567099A4 (en) Improved endoprostheses and methods of manufacture
AU2003208921A1 (en) Emitter and method of making
WO2004064737A3 (en) Therapeutics compositions
AU2003282558A1 (en) Nanopellets and method of making nanopellets
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003294521A1 (en) Toy construction block and method of manufacturing same
GB0303609D0 (en) Novel therapeutic method and compositions
TW200508233A (en) Chk-1 inhibitors
WO2004030634A3 (en) Therapeutic compositions
AU2003235506A1 (en) Targeted enzymes and methods of making and using targeted enzymes.
AU2003241136A1 (en) Microlens and method of making same
AU2002246950A1 (en) Hydrocapsules and method of preparation
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
AU2003216354A1 (en) Modulators of paraptosis and related methods
IL163596A0 (en) Cd40 splice variants, compositions for making and methods of using thesame
EP1517879A4 (en) Aminoalkylphenols, methods of using and making the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP